

Cover Story
Free
By Matthew Bin Han Ong
Joyce Shoffner would never have predicted that Duke University, an institution she revered and at one time worked for, would put her in a breast cancer clinical trial testing a fraudulent technology.
In Brief
Drugs & Targets
Trending Stories
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - California Institute of Regenerative Medicine and Cancer Research: A promise broken?
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Lou Weiner to step down as director of Georgetown’s Lombardi CCC after 18 years
- After a year, Stephenson institute sees a broader role in funding pancreatic cancer research, fostering collaborations
“We are not just funding research. We are building a trusted community.”












